You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAripiprazole
Accession NumberDB01238  (APRD00638)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.
Structure
Thumb
Synonyms
Abilify
Abilitat
Aripiprazol
Aripiprazole
Aripiprazolum
OPC 31
External Identifiers
  • OPC-14597
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbilifyTablet20.0 mgOralBristol Myers Squibb Canada2009-09-30Not applicableCanada
AbilifyTablet15 mg/1OralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
AbilifyTablet5 mg/1OralCarilion Materials Management2002-11-15Not applicableUs
AbilifyTablet30 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not applicableUs
AbilifyTablet20 mg/1OralCardinal Health2002-11-15Not applicableUs
AbilifyTablet5 mg/1OralTYA Pharmaceuticals2002-11-15Not applicableUs
AbilifyTablet2 mg/1OralSTAT Rx USA LLC2002-11-15Not applicableUs
AbilifyTablet20 mg/1OralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-28Not applicableUs
AbilifyTablet30 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-11-15Not applicableUs
AbilifyTablet2 mg/1Oralbryant ranch prepack2002-11-15Not applicableUs
AbilifyInjection, solution9.75 mg/1.3mLIntramuscularOtsuka America Pharmaceutical, Inc.2006-09-20Not applicableUs
AbilifyTablet15 mg/1OralRebel Distributors Corp.2002-11-15Not applicableUs
AbilifyTablet10 mg/1OralCardinal Health2002-11-15Not applicableUs
AbilifyTablet5.0 mgOralBristol Myers Squibb Canada2009-09-30Not applicableCanada
AbilifyTablet2 mg/1OralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
AbilifyTablet30.0 mgOralBristol Myers Squibb Canada2009-09-30Not applicableCanada
AbilifyTablet20 mg/1OralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
AbilifyTablet2 mg/1OralCarilion Materials Management2002-11-15Not applicableUs
AbilifyTablet2 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not applicableUs
AbilifyTablet15 mg/1OralCardinal Health2002-11-15Not applicableUs
AbilifyTablet5 mg/1OralH.J. Harkins Company, Inc.2002-11-15Not applicableUs
AbilifyTablet15 mg/1OralTYA Pharmaceuticals2002-11-15Not applicableUs
AbilifyTablet, orally disintegrating10 mg/1OralOtsuka America Pharmaceutical, Inc.2006-06-07Not applicableUs
AbilifyTablet5 mg/1OralSTAT Rx USA LLC2002-11-15Not applicableUs
AbilifyTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not applicableUs
AbilifyTablet5 mg/1Oralbryant ranch prepack2002-11-15Not applicableUs
AbilifyTablet20 mg/1OralRebel Distributors Corp.2002-11-15Not applicableUs
AbilifyTablet2 mg/1OralCardinal Health2002-11-15Not applicableUs
AbilifyTablet10.0 mgOralBristol Myers Squibb Canada2009-09-30Not applicableCanada
AbilifyTablet5 mg/1OralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
AbilifyTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-11-15Not applicableUs
AbilifyTablet30 mg/1OralCardinal Health2002-11-15Not applicableUs
AbilifyTablet30 mg/1OralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
AbilifyTablet5 mg/1OralRebel Distributors Corp.2002-11-15Not applicableUs
AbilifyTablet10 mg/1OralPhysicians Total Care, Inc.2006-01-31Not applicableUs
AbilifyTablet10 mg/1OralTYA Pharmaceuticals2002-11-15Not applicableUs
AbilifyTablet, orally disintegrating15 mg/1OralOtsuka America Pharmaceutical, Inc.2006-06-07Not applicableUs
AbilifyTablet5 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-17Not applicableUs
AbilifyTablet10 mg/1Oralbryant ranch prepack2002-11-15Not applicableUs
AbilifyTablet15.0 mgOralBristol Myers Squibb Canada2009-09-30Not applicableCanada
AbilifyTablet10 mg/1OralOtsuka America Pharmaceutical, Inc.2002-11-15Not applicableUs
AbilifyTablet15 mg/1OralCarilion Materials Management2002-11-15Not applicableUs
AbilifyTablet5 mg/1OralREMEDYREPACK INC.2013-05-102016-03-31Us
AbilifyTablet5 mg/1OralCardinal Health2002-11-15Not applicableUs
AbilifyTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-11-15Not applicableUs
AbilifyTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2002-11-15Not applicableUs
AbilifySolution1 mg/mLOralOtsuka America Pharmaceutical, Inc.2004-12-10Not applicableUs
AbilifyTablet10 mg/1OralRebel Distributors Corp.2002-11-15Not applicableUs
AbilifyTablet2 mg/1OralPhysicians Total Care, Inc.2011-07-18Not applicableUs
AbilifyTablet2.0 mgOralBristol Myers Squibb Canada2009-09-30Not applicableCanada
AbilifyTablet15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-06-03Not applicableUs
AbilifyTablet2 mg/1OralTYA Pharmaceuticals2002-11-15Not applicableUs
Abilify MaintenaInjection, powder, for suspension, extended release300 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaKitOtsuka America Pharmaceutical, Inc.2014-10-08Not applicableUs
Abilify MaintenaInjection, powder, for suspension, extended release300 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaInjection, powder, for suspension, extended release400 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaInjection, powder, for suspension, extended release400 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaKitOtsuka America Pharmaceutical, Inc.2013-02-28Not applicableUs
Abilify MaintenaInjection, powder, for suspension, extended release; Kit300 mgIntramuscularOtsuka Pharmaceutical Co Ltd2014-03-27Not applicableCanada
Abilify MaintenaInjection, powder, for suspension, extended release300 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaKitOtsuka America Pharmaceutical, Inc.2013-02-28Not applicableUs
Abilify MaintenaInjection, powder, for suspension, extended release300 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaInjection, powder, for suspension, extended release; Kit400 mgIntramuscularOtsuka Pharmaceutical Co Ltd2014-03-27Not applicableCanada
Abilify MaintenaInjection, powder, for suspension, extended release400 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaInjection, powder, for suspension, extended release400 mgIntramuscularOtsuka Pharmaceutical Europe Ltd2013-11-15Not applicableEu
Abilify MaintenaKitOtsuka America Pharmaceutical, Inc.2014-10-08Not applicableUs
AristadaInjection, suspension, extended release662 mg/2.4mLIntramuscularAlkermes, Inc.2015-10-05Not applicableUs
AristadaInjection, suspension, extended release882 mg/3.2mLIntramuscularAlkermes, Inc.2015-10-05Not applicableUs
AristadaInjection, suspension, extended release441 mg/1.6mLIntramuscularAlkermes, Inc.2015-10-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbilifyTablet15 mg/1OralREMEDYREPACK INC.2010-12-142015-12-29Us
AripiprazoleTablet2 mg/1OralTrigen Laboratories, LLC2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet10 mg/1OralScie Gen Pharmaceuticals Inc2016-09-29Not applicableUs
AripiprazoleTablet15 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet20 mg/1OralSafecor Health, LLC2015-12-01Not applicableUs
AripiprazoleTablet20 mg/1OralExelan Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet30 mg/1OralMacleods Pharmaceuticals Limited2016-10-08Not applicableUs
AripiprazoleTablet5 mg/1OralAmerican Health Packaging2015-06-05Not applicableUs
AripiprazoleTablet5 mg/1OralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralDr.reddy’s Laboratories Inc2016-09-29Not applicableUs
AripiprazoleTablet20 mg/1OralAv Pak2016-04-28Not applicableUs
AripiprazoleTablet15 mg/1OralAv Kare, Inc.2015-08-06Not applicableUs
AripiprazoleTablet15 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
AripiprazoleTablet30 mg/1OralAurobindo Pharma Limited2015-10-08Not applicableUs
AripiprazoleTablet5 mg/1OralApotex Corp2015-07-24Not applicableUs
AripiprazoleTablet2 mg/1OralMajor Pharmaceuticals2015-08-25Not applicableUs
AripiprazoleTablet30 mg/1OralAmerican Health Packaging2015-06-05Not applicableUs
AripiprazoleTablet30 mg/1OralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralTrigen Laboratories, LLC2015-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-28Not applicableUs
AripiprazoleTablet15 mg/1OralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet2 mg/1OralAv Pak2016-04-28Not applicableUs
AripiprazoleTablet, orally disintegrating15 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet10 mg/1OralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
AripiprazoleTablet5 mg/1OralAurobindo Pharma Limited2015-10-08Not applicableUs
AripiprazoleTablet10 mg/1OralMacleods Pharmaceuticals Limited2016-10-08Not applicableUs
AripiprazoleTablet30 mg/1OralApotex Corp2015-07-24Not applicableUs
AripiprazoleTablet20 mg/1OralMajor Pharmaceuticals2015-08-25Not applicableUs
AripiprazoleTablet20 mg/1OralTeva Pharmaceuticals Usa, Inc.2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralREMEDYREPACK INC.2015-12-03Not applicableUs
AripiprazoleTablet30 mg/1OralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet30 mg/1OralDr.reddy’s Laboratories Inc2016-09-29Not applicableUs
AripiprazoleTablet2 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet5 mg/1OralSafecor Health, LLC2015-12-01Not applicableUs
AripiprazoleTablet5 mg/1OralExelan Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralTrigen Laboratories, LLC2015-04-28Not applicableUs
AripiprazoleTablet15 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet2 mg/1OralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet15 mg/1OralScie Gen Pharmaceuticals Inc2016-09-29Not applicableUs
AripiprazoleTablet20 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet30 mg/1OralSafecor Health, LLC2015-12-01Not applicableUs
AripiprazoleTablet30 mg/1OralExelan Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralAmerican Health Packaging2015-06-05Not applicableUs
AripiprazoleTablet10 mg/1OralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralMajor Pharmaceuticals2015-08-25Not applicableUs
AripiprazoleTablet5 mg/1OralTeva Pharmaceuticals Usa, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralREMEDYREPACK INC.2015-05-19Not applicableUs
AripiprazoleTablet10 mg/1OralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralDr.reddy’s Laboratories Inc2016-09-29Not applicableUs
AripiprazoleTablet30 mg/1OralAv Pak2016-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralAv Kare, Inc.2015-08-06Not applicableUs
AripiprazoleTablet20 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
AripiprazoleSolution1 mg/mLOralApotex Corp.2015-10-08Not applicableUs
AripiprazoleTablet10 mg/1OralApotex Corp2015-07-24Not applicableUs
AripiprazoleTablet10 mg/1OralAurobindo Pharma Limited2015-10-08Not applicableUs
AripiprazoleTablet20 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
AripiprazoleTablet2 mg/1OralAv Kare, Inc.2015-08-06Not applicableUs
AripiprazoleTablet30 mg/1OralTrigen Laboratories, LLC2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-28Not applicableUs
AripiprazoleTablet20 mg/1OralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralAv Pak2016-04-28Not applicableUs
AripiprazoleTablet2 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
AripiprazoleTablet15 mg/1OralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
AripiprazoleTablet5 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet10 mg/1OralSafecor Health, LLC2015-12-01Not applicableUs
AripiprazoleTablet10 mg/1OralExelan Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet15 mg/1OralMacleods Pharmaceuticals Limited2016-10-08Not applicableUs
AripiprazoleTablet2 mg/1OralApotex Corp2015-07-24Not applicableUs
AripiprazoleTablet30 mg/1OralMajor Pharmaceuticals2015-08-25Not applicableUs
AripiprazoleTablet30 mg/1OralTeva Pharmaceuticals Usa, Inc.2015-04-28Not applicableUs
AripiprazoleTablet2 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet, orally disintegrating10 mg/1OralAlembic Pharmaceuticals Limited2015-05-21Not applicableUs
AripiprazoleTablet2 mg/1OralScie Gen Pharmaceuticals Inc2016-09-29Not applicableUs
AripiprazoleTablet15 mg/1OralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralTrigen Laboratories, LLC2015-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet5 mg/1OralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralScie Gen Pharmaceuticals Inc2016-09-29Not applicableUs
AripiprazoleTablet30 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet2 mg/1OralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
AripiprazoleTablet5 mg/1OralREMEDYREPACK INC.2016-10-21Not applicableUs
AripiprazoleTablet15 mg/1OralAmerican Health Packaging2015-06-05Not applicableUs
AripiprazoleTablet15 mg/1OralApotex Corp2015-07-24Not applicableUs
AripiprazoleTablet10 mg/1OralMajor Pharmaceuticals2015-08-25Not applicableUs
AripiprazoleTablet10 mg/1OralTeva Pharmaceuticals Usa, Inc.2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralREMEDYREPACK INC.2015-06-15Not applicableUs
AripiprazoleTablet15 mg/1OralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet15 mg/1OralDr.reddy’s Laboratories Inc2016-09-29Not applicableUs
AripiprazoleTablet20 mg/1OralREMEDYREPACK INC.2016-08-31Not applicableUs
AripiprazoleTablet30 mg/1OralAv Kare, Inc.2015-08-06Not applicableUs
AripiprazoleTablet30 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
AripiprazoleTablet2 mg/1OralMacleods Pharmaceuticals Limited2016-10-08Not applicableUs
AripiprazoleTablet10 mg/1OralAv Pak2016-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
AripiprazoleTablet20 mg/1OralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
AripiprazoleTablet15 mg/1OralAurobindo Pharma Limited2015-10-08Not applicableUs
AripiprazoleSolution1 mg/mLOralAmneal Pharmaceuticals of New York, LLC2015-08-17Not applicableUs
AripiprazoleTablet5 mg/1OralAv Kare, Inc.2015-08-06Not applicableUs
AripiprazoleTablet, orally disintegrating10 mg/1OralTrigen Laboratories, LLC2015-05-21Not applicableUs
AripiprazoleTablet30 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-28Not applicableUs
AripiprazoleTablet30 mg/1OralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet, orally disintegrating15 mg/1OralAlembic Pharmaceuticals Limited2015-05-21Not applicableUs
AripiprazoleTablet5 mg/1OralScie Gen Pharmaceuticals Inc2016-09-29Not applicableUs
AripiprazoleTablet10 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet15 mg/1OralSafecor Health, LLC2015-12-01Not applicableUs
AripiprazoleTablet15 mg/1OralExelan Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralMacleods Pharmaceuticals Limited2016-10-08Not applicableUs
AripiprazoleTablet2 mg/1OralAmerican Health Packaging2015-06-05Not applicableUs
AripiprazoleTablet2 mg/1OralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet2 mg/1OralTeva Pharmaceuticals Usa, Inc.2015-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralAmerican Health Packaging2015-06-05Not applicableUs
AripiprazoleTablet20 mg/1OralTorrent Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet15 mg/1OralTrigen Laboratories, LLC2015-04-28Not applicableUs
AripiprazoleTablet30 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet10 mg/1OralCamber Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet30 mg/1OralScie Gen Pharmaceuticals Inc2016-09-29Not applicableUs
AripiprazoleTablet, orally disintegrating10 mg/1OralAlembic Pharmaceuticals Inc.2016-07-07Not applicableUs
AripiprazoleTablet5 mg/1OralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
AripiprazoleTablet2 mg/1OralAurobindo Pharma Limited2015-10-08Not applicableUs
AripiprazoleTablet20 mg/1OralApotex Corp2015-07-24Not applicableUs
AripiprazoleTablet15 mg/1OralMajor Pharmaceuticals2015-08-25Not applicableUs
AripiprazoleTablet15 mg/1OralTeva Pharmaceuticals Usa, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralREMEDYREPACK INC.2015-10-13Not applicableUs
AripiprazoleTablet20 mg/1OralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet20 mg/1OralDr.reddy’s Laboratories Inc2016-09-29Not applicableUs
AripiprazoleTablet10 mg/1OralREMEDYREPACK INC.2016-09-06Not applicableUs
AripiprazoleTablet2 mg/1OralSafecor Health, LLC2015-12-01Not applicableUs
AripiprazoleTablet2 mg/1OralExelan Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralMacleods Pharmaceuticals Limited2016-10-08Not applicableUs
AripiprazoleTablet, orally disintegrating15 mg/1OralTrigen Laboratories, LLC2015-05-21Not applicableUs
AripiprazoleTablet2 mg/1OralDr.reddy’s Laboratories Inc2016-09-29Not applicableUs
AripiprazoleTablet10 mg/1OralCarilion Materials Management2015-04-28Not applicableUs
AripiprazoleTablet15 mg/1OralAv Pak2016-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralAmneal Pharmaceuticals of New York, LLC2016-06-20Not applicableUs
AripiprazoleTablet30 mg/1OralGolden State Medical Supply, Inc.2015-07-28Not applicableUs
AripiprazoleTablet20 mg/1OralAurobindo Pharma Limited2015-10-08Not applicableUs
AripiprazoleTablet2 mg/1OralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet10 mg/1OralAv Kare, Inc.2015-08-06Not applicableUs
Aripiprazole AccordTablet10 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet10 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet5 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet30 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole AccordTablet15 mgOralAccord Healthcare Ltd2015-11-16Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet5 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet15 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet10 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Mylan PharmaTablet30 mgOralMylan S.A.S2015-06-30Not applicableEu
Aripiprazole Oral SolutionSolution1 mg/mLOralSilarx Pharmaceuticals, Inc2015-08-17Not applicableUs
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet10 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet5 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet15 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet20 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole SandozTablet30 mgOralSandoz Gmb H2015-08-20Not applicableEu
Aripiprazole ZentivaTablet10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet10 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet5 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet15 mgOralZentiva, K.S.2015-06-25Not applicableEu
Aripiprazole ZentivaTablet, orally disintegrating30 mgOralZentiva, K.S.2015-06-25Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbilitatNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Aripiprazole lauroxil
1259305-29-7
Thumb
  • InChI Key: DDINXHAORAAYAD-UHFFFAOYSA-N
  • Monoisotopic Mass: 659.3256625
  • Average Mass: 660.72
DBSALT001351
Categories
UNII82VFR53I78
CAS number129722-12-9
WeightAverage: 448.385
Monoisotopic: 447.148032537
Chemical FormulaC23H27Cl2N3O2
InChI KeyCEUORZQYGODEFX-UHFFFAOYSA-N
InChI
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
IUPAC Name
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
SMILES
ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
Structured Indications
PharmacodynamicsAripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Mechanism of actionAripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(2) dopamine receptorProteinyes
antagonist
partial agonist
HumanP14416 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
partial agonist
HumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknown
antagonist
HumanP28222 details
5-hydroxytryptamine receptor 1DProteinunknown
antagonist
HumanP28221 details
5-hydroxytryptamine receptor 1EProteinunknown
antagonist
HumanP28566 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 3AProteinunknown
antagonist
HumanP46098 details
5-hydroxytryptamine receptor 6Proteinunknown
antagonist
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
D(1A) dopamine receptorProteinunknown
antagonist
partial agonist
HumanP21728 details
D(1B) dopamine receptorProteinunknown
antagonist
partial agonist
HumanP21918 details
D(3) dopamine receptorProteinunknown
antagonist
partial agonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
partial agonist
HumanP21917 details
Histamine H1 receptorProteinno
antagonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinno
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinno
antagonist
HumanP35368 details
Alpha-2A adrenergic receptorProteinno
antagonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinno
antagonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinno
antagonist
other/unknown
HumanP18825 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 4.9 L/kg
Protein binding>99%
Metabolism

Hepatic.

Route of eliminationLess than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.
Half life75-146 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineAripiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAripiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Aripiprazole can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Aripiprazole.Approved, Investigational
AcebutololAripiprazole may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Aripiprazole can be decreased when it is combined with Acetaminophen.Approved
AcetazolamideAripiprazole may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole.Withdrawn
adipiplonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Agomelatine.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Aripiprazole.Experimental
AlclometasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Alclometasone.Approved
AldesleukinAripiprazole may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Aripiprazole.Approved, Illicit
AlimemazineThe serum concentration of Aripiprazole can be decreased when it is combined with Alimemazine.Approved, Vet Approved
AliskirenAripiprazole may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe serum concentration of Aripiprazole can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Aripiprazole.Approved
AmifostineAripiprazole may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAripiprazole may increase the hypotensive activities of Amiloride.Approved
AminoglutethimideThe serum concentration of Aripiprazole can be decreased when it is combined with Aminoglutethimide.Approved
AmiodaroneThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Aripiprazole can be increased when it is combined with Amitriptyline.Approved
AmlodipineAripiprazole may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amperozide.Experimental
AmphetamineAripiprazole may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BAripiprazole may increase the hypotensive activities of Amphotericin B.Approved, Investigational
Amyl NitriteAripiprazole may increase the hypotensive activities of Amyl Nitrite.Approved
AnagrelideAripiprazole may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineAripiprazole may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineAripiprazole may increase the hypotensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Aripiprazole can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil.Approved, Investigational
ArotinololAripiprazole may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideAripiprazole may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Aripiprazole can be decreased when it is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Articaine.Approved
AsenapineAripiprazole may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Aripiprazole can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAripiprazole may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Atorvastatin.Approved
AvasimibeThe serum concentration of Aripiprazole can be decreased when it is combined with Avasimibe.Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Azaperone.Vet Approved
AzatadineThe serum concentration of Aripiprazole can be decreased when it is combined with Azatadine.Approved
AzelastineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Azelastine.Approved
Azilsartan medoxomilAripiprazole may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzithromycinAripiprazole may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Aripiprazole.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.Illicit
BarnidipineAripiprazole may increase the hypotensive activities of Barnidipine.Approved
BedaquilineAripiprazole may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilAripiprazole may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideAripiprazole may increase the hypotensive activities of Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Aripiprazole.Approved
BenzphetamineAripiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzyl alcohol.Approved
BepridilAripiprazole may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololAripiprazole may increase the hypotensive activities of Betaxolol.Approved
BexaroteneThe serum concentration of Aripiprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Aripiprazole can be increased when it is combined with Bicalutamide.Approved
BisoprololAripiprazole may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Aripiprazole can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Aripiprazole can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Aripiprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumAripiprazole may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brexpiprazole.Approved
BrimonidineAripiprazole may increase the hypotensive activities of Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.Approved, Illicit
BromocriptineAripiprazole may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brotizolam.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Aripiprazole.Withdrawn
BumetanideAripiprazole may increase the hypotensive activities of Bumetanide.Approved
BupivacaineAripiprazole may increase the hypotensive activities of Bupivacaine.Approved, Investigational
BuprenorphineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Aripiprazole can be increased when it is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aripiprazole.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aripiprazole.Approved
CalcitriolThe serum concentration of Aripiprazole can be decreased when it is combined with Calcitriol.Approved, Nutraceutical
CanagliflozinAripiprazole may increase the hypotensive activities of Canagliflozin.Approved
CandesartanAripiprazole may increase the hypotensive activities of Candesartan.Approved
CaptoprilAripiprazole may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinAripiprazole may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol.Approved
CarteololAripiprazole may increase the hypotensive activities of Carteolol.Approved
CarvedilolAripiprazole may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Aripiprazole.Experimental
CefradineThe serum concentration of Aripiprazole can be decreased when it is combined with Cefradine.Approved
CelecoxibThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Aripiprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Cerivastatin.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aripiprazole.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Aripiprazole.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aripiprazole.Approved
ChloroquineThe serum concentration of Aripiprazole can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideAripiprazole may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorphenamine.Approved
ChlorphenesinThe serum concentration of Aripiprazole can be decreased when it is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineAripiprazole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneAripiprazole may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorzoxazone.Approved
CholecalciferolThe serum concentration of Aripiprazole can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Aripiprazole.Experimental
CilazaprilAripiprazole may increase the hypotensive activities of Cilazapril.Approved
CilnidipineAripiprazole may increase the hypotensive activities of Cilnidipine.Approved
CilostazolThe serum concentration of Aripiprazole can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Aripiprazole.Approved, Vet Approved
CiprofloxacinThe serum concentration of Aripiprazole can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideAripiprazole may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Aripiprazole can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Aripiprazole can be increased when it is combined with Clemastine.Approved
ClevidipineThe serum concentration of Aripiprazole can be decreased when it is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clidinium.Approved
ClobazamThe serum concentration of Aripiprazole can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineAripiprazole may increase the hypotensive activities of Clofarabine.Approved, Investigational
ClofibrateThe serum concentration of Aripiprazole can be decreased when it is combined with Clofibrate.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with clomethiazole.Investigational
ClomipramineThe serum concentration of Aripiprazole can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clonazepam.Approved, Illicit
ClonidineAripiprazole may increase the hypotensive activities of Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aripiprazole.Approved, Illicit
ClotrimazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Aripiprazole can be decreased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Aripiprazole can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Aripiprazole can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe serum concentration of Aripiprazole can be increased when it is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Aripiprazole can be decreased when it is combined with Colchicine.Approved
ConivaptanThe serum concentration of Aripiprazole can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Aripiprazole can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.Approved
CyclophosphamideThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Aripiprazole can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.Approved
DalfopristinThe serum concentration of Aripiprazole can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Aripiprazole can be increased when it is combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.Approved
DapagliflozinAripiprazole may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Aripiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dapoxetine.Investigational
DarifenacinThe serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Aripiprazole can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Aripiprazole can be increased when it is combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Aripiprazole.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with deramciclane.Investigational
DesfluraneAripiprazole may increase the hypotensive activities of Desflurane.Approved
DesipramineThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Aripiprazole.Approved
DetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine.Approved
DexmedetomidineAripiprazole may increase the hypotensive activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineAripiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Aripiprazole can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aripiprazole.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Aripiprazole.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Aripiprazole.Approved, Illicit, Vet Approved
DiclofenamideAripiprazole may increase the hypotensive activities of Diclofenamide.Approved
DicloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiethylpropionAripiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Aripiprazole can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Aripiprazole can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dimenhydrinate.Approved
DinutuximabAripiprazole may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe serum concentration of Aripiprazole can be increased when it is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aripiprazole.Approved, Illicit
DipyridamoleAripiprazole may increase the hypotensive activities of Dipyridamole.Approved
DisopyramideAripiprazole may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe serum concentration of Aripiprazole can be increased when it is combined with Disulfiram.Approved
DofetilideAripiprazole may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronThe serum concentration of Aripiprazole can be increased when it is combined with Dolasetron.Approved
DomperidoneAripiprazole may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doramectin.Vet Approved
DoxazosinAripiprazole may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Aripiprazole can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Aripiprazole can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Aripiprazole is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Illicit
DronedaroneThe serum concentration of Aripiprazole can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Aripiprazole.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Aripiprazole.Approved
EcgonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Aripiprazole is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineAripiprazole may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Aripiprazole can be decreased when it is combined with Eletriptan.Approved, Investigational
EliglustatThe serum concentration of Aripiprazole can be increased when it is combined with Eliglustat.Approved
EmpagliflozinAripiprazole may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilAripiprazole may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAripiprazole may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Aripiprazole.Approved, Vet Approved
EntacaponeThe serum concentration of Aripiprazole can be increased when it is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.Approved
EplerenoneAripiprazole may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolAripiprazole may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAripiprazole may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aripiprazole.Approved
ErythromycinThe serum concentration of Aripiprazole can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramAripiprazole may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololAripiprazole may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Aripiprazole.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aripiprazole.Approved
Etacrynic acidAripiprazole may increase the hypotensive activities of Etacrynic acid.Approved
EthanolThe serum concentration of Aripiprazole can be decreased when it is combined with Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aripiprazole.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Aripiprazole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etoperidone.Approved
EtoposideThe serum concentration of Aripiprazole can be decreased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Aripiprazole can be decreased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Aripiprazole.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ezogabine.Approved
FelbamateThe serum concentration of Aripiprazole can be decreased when it is combined with Felbamate.Approved
FelodipineAripiprazole may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamAripiprazole may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aripiprazole.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.Approved
FexofenadineThe serum concentration of Aripiprazole can be increased when it is combined with Fexofenadine.Approved
FimasartanAripiprazole may increase the hypotensive activities of Fimasartan.Approved
FlecainideThe serum concentration of Aripiprazole can be increased when it is combined with Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.Approved
FlucloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Flucloxacillin.Approved
FluconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunitrazepam.Approved, Illicit
FluorometholoneThe serum concentration of Aripiprazole can be decreased when it is combined with Fluorometholone.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.Approved, Vet Approved
FlupentixolAripiprazole may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Aripiprazole can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluticasone Propionate.Approved
FluvastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Aripiprazole can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Aripiprazole can be increased when it is combined with Fosaprepitant.Approved
FosinoprilAripiprazole may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Aripiprazole.Approved, Investigational
FurosemideAripiprazole may increase the hypotensive activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Aripiprazole can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aripiprazole.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with gabapentin enacarbil.Approved
Gadobenic acidAripiprazole may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Aripiprazole can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe serum concentration of Aripiprazole can be decreased when it is combined with Gemfibrozil.Approved
GemifloxacinAripiprazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Aripiprazole.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Aripiprazole.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Aripiprazole.Approved
Glycerol PhenylbutyrateThe serum concentration of Aripiprazole can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GoserelinAripiprazole may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronAripiprazole may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GriseofulvinThe serum concentration of Aripiprazole can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
GuanethidineThe serum concentration of Aripiprazole can be decreased when it is combined with Guanethidine.Approved
GuanfacineAripiprazole may increase the hypotensive activities of Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Aripiprazole.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Aripiprazole.Approved, Illicit, Withdrawn
HaloperidolAripiprazole may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneAripiprazole may increase the hypotensive activities of Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Hexobarbital.Approved
HydralazineAripiprazole may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideAripiprazole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortamateThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortamate.Approved
HydroflumethiazideAripiprazole may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole.Approved, Illicit
Hydroxyamphetamine hydrobromideAripiprazole may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
IbutilideAripiprazole may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Aripiprazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Aripiprazole can be decreased when it is combined with Ifosfamide.Approved
IloperidoneThe serum concentration of Aripiprazole can be increased when it is combined with Iloperidone.Approved
IloprostAripiprazole may increase the hypotensive activities of Iloprost.Approved, Investigational
ImatinibThe serum concentration of Aripiprazole can be increased when it is combined with Imatinib.Approved
ImidaprilAripiprazole may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indalpine.Investigational, Withdrawn
IndapamideAripiprazole may increase the hypotensive activities of Indapamide.Approved
IndinavirThe serum concentration of Aripiprazole can be increased when it is combined with Indinavir.Approved
IndoraminAripiprazole may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Aripiprazole.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Aripiprazole.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Aripiprazole.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Aripiprazole.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Aripiprazole.Approved
IrbesartanAripiprazole may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Aripiprazole can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidAripiprazole may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneAripiprazole may increase the hypotensive activities of Isoflurane.Approved, Vet Approved
IsoniazidThe serum concentration of Aripiprazole can be increased when it is combined with Isoniazid.Approved
Isosorbide DinitrateAripiprazole may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateAripiprazole may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineAripiprazole may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe serum concentration of Aripiprazole can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Aripiprazole can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolAripiprazole may increase the hypotensive activities of Labetalol.Approved
LacidipineAripiprazole may increase the hypotensive activities of Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Aripiprazole can be increased when it is combined with Lapatinib.Approved, Investigational
LenvatinibAripiprazole may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineAripiprazole may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LeuprolideAripiprazole may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levetiracetam.Approved, Investigational
LevobunololAripiprazole may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineAripiprazole may increase the hypotensive activities of Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocetirizine.Approved
LevodopaAripiprazole may increase the hypotensive activities of Levodopa.Approved
LevofloxacinAripiprazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Aripiprazole.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Aripiprazole.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aripiprazole.Approved
LevosimendanAripiprazole may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Aripiprazole.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Aripiprazole.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aripiprazole.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Aripiprazole.Approved
LisdexamfetamineAripiprazole may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilAripiprazole may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Aripiprazole.Approved
LofentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lofentanil.Illicit
LofexidineAripiprazole may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Aripiprazole can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Aripiprazole can be increased when it is combined with Lomustine.Approved
LopinavirThe serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Aripiprazole can be decreased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.Approved
LorcaserinThe serum concentration of Aripiprazole can be increased when it is combined with Lorcaserin.Approved
LosartanAripiprazole may increase the hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Aripiprazole can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aripiprazole.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Aripiprazole can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Aripiprazole can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Aripiprazole can be increased when it is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
MannitolAripiprazole may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Maprotiline.Approved
MecamylamineAripiprazole may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Aripiprazole can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Aripiprazole.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Melperone.Approved
MephedroneAripiprazole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAripiprazole may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aripiprazole.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.Approved, Illicit
MequitazineAripiprazole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Aripiprazole.Approved
MetamizoleThe serum concentration of Aripiprazole can be decreased when it is combined with Metamizole.Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineAripiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methaqualone.Illicit, Withdrawn
MethazolamideAripiprazole may increase the hypotensive activities of Methazolamide.Approved
MethimazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methimazole.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Aripiprazole.Approved
MethotrimeprazineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxsalenThe serum concentration of Aripiprazole can be increased when it is combined with Methoxsalen.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aripiprazole.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.Approved
MethyclothiazideAripiprazole may increase the hypotensive activities of Methyclothiazide.Approved
MethyldopaAripiprazole may increase the hypotensive activities of Methyldopa.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Aripiprazole.Approved
MetipranololAripiprazole may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.Approved, Investigational
MetolazoneAripiprazole may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Aripiprazole.Approved, Investigational
MetyraponeThe serum concentration of Aripiprazole can be decreased when it is combined with Metyrapone.Approved
MetyrosineAripiprazole may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Aripiprazole.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Aripiprazole.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Aripiprazole.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
MinoxidilAripiprazole may increase the hypotensive activities of Minoxidil.Approved
MirabegronThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.Approved
MirtazapineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
MitotaneThe serum concentration of Aripiprazole can be decreased when it is combined with Mitotane.Approved
MMDAAripiprazole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe serum concentration of Aripiprazole can be increased when it is combined with Moclobemide.Approved
ModafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilAripiprazole may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Molindone.Approved
MorphineAripiprazole may increase the hypotensive activities of Morphine.Approved, Investigational
MoxifloxacinAripiprazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineAripiprazole may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
NadololAripiprazole may increase the hypotensive activities of Nadolol.Approved
NafcillinThe serum concentration of Aripiprazole can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aripiprazole.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
NebivololAripiprazole may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Aripiprazole can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir.Approved
NesiritideAripiprazole may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Aripiprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Aripiprazole can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Aripiprazole can be decreased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Aripiprazole can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Aripiprazole can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineAripiprazole may increase the hypotensive activities of Nilvadipine.Approved
NimodipineAripiprazole may increase the hypotensive activities of Nimodipine.Approved
NisoldipineAripiprazole may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrazepam.Approved
NitrendipineAripiprazole may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideAripiprazole may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinAripiprazole may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideAripiprazole may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Normethadone.Approved, Illicit
NortriptylineThe serum concentration of Aripiprazole can be increased when it is combined with Nortriptyline.Approved
ObinutuzumabAripiprazole may increase the hypotensive activities of Obinutuzumab.Approved
OfloxacinAripiprazole may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Aripiprazole can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Aripiprazole can be increased when it is combined with Olaparib.Approved
OlmesartanAripiprazole may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Aripiprazole can be increased when it is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Aripiprazole can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Aripiprazole can be decreased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Aripiprazole can be increased when it is combined with Ospemifene.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aripiprazole.Approved
OxcarbazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxetacaine.Investigational
OxiconazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Oxiconazole.Approved
OxprenololAripiprazole may increase the hypotensive activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Aripiprazole.Approved
OxybutyninThe serum concentration of Aripiprazole can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aripiprazole.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.Approved
PaliperidoneAripiprazole may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Aripiprazole can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.Approved
PapaverineAripiprazole may increase the hypotensive activities of Papaverine.Approved
ParaldehydeAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aripiprazole.Approved, Investigational
PazopanibThe serum concentration of Aripiprazole can be increased when it is combined with Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe serum concentration of Aripiprazole can be decreased when it is combined with Pegvisomant.Approved
PenbutololAripiprazole may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe serum concentration of Aripiprazole can be increased when it is combined with Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.Approved, Vet Approved
PentobarbitalThe serum concentration of Aripiprazole can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
PerazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perazine.Investigational
PerflutrenAripiprazole may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilAripiprazole may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perospirone.Approved
PerphenazineThe serum concentration of Aripiprazole can be increased when it is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aripiprazole.Approved
PhenelzineAripiprazole may increase the hypotensive activities of Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Aripiprazole.Approved, Withdrawn
PhenobarbitalThe serum concentration of Aripiprazole can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineAripiprazole may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenoxyethanol.Approved
PhentermineAripiprazole may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineAripiprazole may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideAripiprazole may increase the QTc-prolonging activities of Pimozide.Approved
PindololAripiprazole may increase the hypotensive activities of Pindolol.Approved
PioglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneAripiprazole may increase the hypotensive activities of Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Aripiprazole.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleAripiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Aripiprazole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pramocaine.Approved
PravastatinThe serum concentration of Aripiprazole can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam.Approved, Illicit
PraziquantelThe serum concentration of Aripiprazole can be increased when it is combined with Praziquantel.Approved, Vet Approved
PrazosinAripiprazole may increase the hypotensive activities of Prazosin.Approved
PrednisoneThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Aripiprazole.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Aripiprazole.Approved
PrimaquineThe serum concentration of Aripiprazole can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Aripiprazole can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Aripiprazole can be decreased when it is combined with Probenecid.Approved
ProcainamideAripiprazole may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Aripiprazole.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aripiprazole.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.Approved, Vet Approved
ProgesteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Aripiprazole can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Aripiprazole can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Aripiprazole.Approved, Vet Approved
PropofolAripiprazole may increase the hypotensive activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propoxycaine.Approved
PropranololAripiprazole may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Aripiprazole is combined with PSD502.Investigational
PseudoephedrineAripiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
PyridostigmineThe serum concentration of Aripiprazole can be decreased when it is combined with Pyridostigmine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quazepam.Approved, Illicit
QuetiapineAripiprazole may increase the hypotensive activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Aripiprazole.Approved
QuinaprilAripiprazole may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Aripiprazole can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Aripiprazole can be decreased when it is combined with Quinine.Approved
QuinupristinThe serum concentration of Aripiprazole can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon.Approved, Investigational
RamiprilAripiprazole may increase the hypotensive activities of Ramipril.Approved
RanitidineThe serum concentration of Aripiprazole can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Aripiprazole can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineAripiprazole may increase the hypotensive activities of Rasagiline.Approved
RemifentanilAripiprazole may increase the hypotensive activities of Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Aripiprazole.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ReserpineAripiprazole may increase the hypotensive activities of Reserpine.Approved
RifabutinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Aripiprazole can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Aripiprazole can be decreased when it is combined with Rilpivirine.Approved
RiociguatAripiprazole may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe serum concentration of Aripiprazole can be increased when it is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritanserin.Investigational
RitobegronAripiprazole may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aripiprazole.Approved
RofecoxibThe serum concentration of Aripiprazole can be decreased when it is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Aripiprazole can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Romifidine.Vet Approved
RopiniroleAripiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineAripiprazole may increase the hypotensive activities of Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aripiprazole.Approved, Investigational
RotigotineAripiprazole may increase the sedative activities of Rotigotine.Approved
RufinamideThe serum concentration of Aripiprazole can be decreased when it is combined with Rufinamide.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Aripiprazole is combined with S-Ethylisothiourea.Experimental
SacubitrilAripiprazole may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aripiprazole.Approved, Vet Approved
SelegilineThe serum concentration of Aripiprazole can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe serum concentration of Aripiprazole can be decreased when it is combined with Seratrodast.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Aripiprazole.Approved
SevofluraneAripiprazole may increase the hypotensive activities of Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Aripiprazole can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Aripiprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Aripiprazole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Simvastatin.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Sodium NitriteAripiprazole may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
Sodium phenylbutyrateThe serum concentration of Aripiprazole can be increased when it is combined with Sodium phenylbutyrate.Approved
SotalolAripiprazole may increase the hypotensive activities of Sotalol.Approved
SpironolactoneAripiprazole may increase the hypotensive activities of Spironolactone.Approved
St. John's WortThe serum concentration of Aripiprazole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Aripiprazole can be increased when it is combined with Stiripentol.Approved
StreptokinaseAripiprazole may increase the hypotensive activities of Streptokinase.Approved
SufentanilAripiprazole may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulconazole.Approved
SulfinpyrazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aripiprazole.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole.Approved, Investigational
SuvorexantAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe serum concentration of Aripiprazole can be decreased when it is combined with Tamoxifen.Approved
TamsulosinAripiprazole may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aripiprazole.Approved
TelaprevirThe serum concentration of Aripiprazole can be increased when it is combined with Telaprevir.Approved
TelavancinAripiprazole may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Telithromycin.Approved
TelmisartanAripiprazole may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Aripiprazole.Approved
TemozolomideThe serum concentration of Aripiprazole can be decreased when it is combined with Temozolomide.Approved, Investigational
TemsirolimusThe serum concentration of Aripiprazole can be increased when it is combined with Temsirolimus.Approved
TerazosinAripiprazole may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Aripiprazole can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Aripiprazole can be decreased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Aripiprazole can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole.Approved
TetracaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrodotoxin.Investigational
ThalidomideAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aripiprazole.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Aripiprazole.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Aripiprazole.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Aripiprazole.Approved
ThiothixeneThe serum concentration of Aripiprazole can be increased when it is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Aripiprazole can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Aripiprazole can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiletamine.Vet Approved
TimololAripiprazole may increase the hypotensive activities of Timolol.Approved
TioconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tioconazole.Approved
TipranavirThe serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineAripiprazole may increase the hypotensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.Approved
TolazolineAripiprazole may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.Approved
TolcaponeAripiprazole may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
TopiramateThe serum concentration of Aripiprazole can be decreased when it is combined with Topiramate.Approved
TopotecanThe serum concentration of Aripiprazole can be decreased when it is combined with Topotecan.Approved, Investigational
TorasemideAripiprazole may increase the hypotensive activities of Torasemide.Approved
ToremifeneAripiprazole may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.Approved, Investigational
TrametinibThe serum concentration of Aripiprazole can be decreased when it is combined with Trametinib.Approved
TrandolaprilAripiprazole may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Aripiprazole.Approved, Investigational
TretinoinAripiprazole may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneAripiprazole may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Aripiprazole.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aripiprazole.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Aripiprazole.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trimipramine.Approved
TriprolidineThe serum concentration of Aripiprazole can be increased when it is combined with Triprolidine.Approved
TroglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Troglitazone.Withdrawn
Uc1010The risk or severity of adverse effects can be increased when Aripiprazole is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Aripiprazole.Approved, Investigational
ValsartanAripiprazole may increase the hypotensive activities of Valsartan.Approved, Investigational
VandetanibAripiprazole may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Aripiprazole can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vigabatrin.Approved
VilazodoneThe serum concentration of Aripiprazole can be increased when it is combined with Vilazodone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Aripiprazole.Approved, Investigational
VinblastineThe serum concentration of Aripiprazole can be increased when it is combined with Vinblastine.Approved
VinorelbineThe serum concentration of Aripiprazole can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Aripiprazole.Approved, Investigational
VoriconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Xylazine.Vet Approved
ZafirlukastThe serum concentration of Aripiprazole can be increased when it is combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aripiprazole.Approved, Investigational
ZolpidemAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Aripiprazole.Approved
ZotepineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zotepine.Approved
ZuclopenthixolAripiprazole may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol (possible additive effect to CNS).
  • Food has no significant effect on absorption.
  • Take without regard to meals.
References
Synthesis ReferenceUS5006528
General ReferencesNot Available
External Links
ATC CodesN05AX12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (262 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.992
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7431
P-glycoprotein inhibitor IInhibitor0.9585
P-glycoprotein inhibitor IIInhibitor0.9321
Renal organic cation transporterInhibitor0.5175
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6581
CYP450 2C9 inhibitorInhibitor0.6682
CYP450 2D6 inhibitorInhibitor0.6633
CYP450 2C19 inhibitorInhibitor0.8934
CYP450 3A4 inhibitorInhibitor0.5256
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9104
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.8765
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.62
hERG inhibition (predictor II)Inhibitor0.8814
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular9.75 mg/1.3mL
TabletOral10.0 mg
TabletOral15.0 mg
TabletOral2.0 mg
TabletOral20.0 mg
TabletOral30.0 mg
TabletOral5.0 mg
Injection, powder, for suspension, extended releaseIntramuscular300 mg
Injection, powder, for suspension, extended releaseIntramuscular400 mg
Injection, powder, for suspension, extended release; kitIntramuscular300 mg
Injection, powder, for suspension, extended release; kitIntramuscular400 mg
Kit
SolutionOral1 mg/mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral2 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
TabletOral10 mg
TabletOral15 mg
TabletOral30 mg
TabletOral5 mg
TabletOral20 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral15 mg
Tablet, orally disintegratingOral30 mg
Injection, suspension, extended releaseIntramuscular441 mg/1.6mL
Injection, suspension, extended releaseIntramuscular662 mg/2.4mL
Injection, suspension, extended releaseIntramuscular882 mg/3.2mL
Prices
Unit descriptionCostUnit
Abilify Discmelt 30 10 mg Dispersible Tablet Box636.3USD box
Abilify 30 mg tablet32.12USD tablet
Abilify 15 mg tablet26.07USD tablet
Abilify 10 mg tablet23.53USD tablet
Abilify 5 mg tablet23.53USD tablet
Abilify 2 mg tablet22.25USD tablet
Abilify 20 mg tablet21.99USD tablet
Abilify discmelt 10 mg tablet20.39USD tablet
Abilify discmelt 15 mg tablet20.39USD tablet
Abilify 9.7 mg/1.3 ml vial16.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006528 No1994-10-202014-10-20Us
US6977257 Yes2002-10-242022-10-24Us
US7053092 No2002-01-282022-01-28Us
US7115587 Yes2005-01-212025-01-21Us
US7550445 Yes2005-01-212025-01-21Us
US7807680 No2004-10-192024-10-19Us
US8017615 Yes2004-12-162024-12-16Us
US8030313 No2004-10-192024-10-19Us
US8338427 No2005-03-152025-03-15Us
US8338428 No2003-08-062023-08-06Us
US8399469 No2005-06-292025-06-29Us
US8431576 No2010-10-262030-10-26Us
US8518421 Yes2001-07-242021-07-24Us
US8580796 Yes2003-03-252023-03-25Us
US8642600 Yes2002-07-282022-07-28Us
US8642760 Yes2003-03-252023-03-25Us
US8722679 No2004-10-192024-10-19Us
US8759350 No2007-03-022027-03-02Us
US8759351 No2003-08-062023-08-06Us
US8796276 No2010-06-242030-06-24Us
US8993761 No2002-09-252022-09-25Us
US9034867 No2012-11-072032-11-07Us
US9089567 No2002-01-282022-01-28Us
US9125939 No2006-07-282026-07-28Us
US9193685 No2013-10-242033-10-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00777 mg/mLALOGPS
logP5.21ALOGPS
logP4.9ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability49.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Quinolone
  • Tetrahydroquinolone
  • Tetrahydroquinoline
  • Substituted aniline
  • Dialkylarylamine
  • 1,2-dichlorobenzene
  • N-alkylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. [PubMed:14642974 ]
  2. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925 ]
  3. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30. [PubMed:17265076 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistpartial agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90. [PubMed:16366516 ]
  2. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11. [PubMed:9083792 ]
  3. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21. [PubMed:16925992 ]
  4. Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28. [PubMed:16981227 ]
  5. Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. [PubMed:17501690 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137-40. [PubMed:12063084 ]
  2. Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl). 2004 Apr;172(4):415-21. Epub 2003 Nov 28. [PubMed:14647959 ]
  3. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004 Jan 1;483(1):45-53. [PubMed:14709325 ]
  4. Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. [PubMed:15257633 ]
  5. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005 May 10;1043(1-2):32-41. [PubMed:15862515 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistpartial agonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonistother/unknown
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54